SCHEMBL1306767

SCHEMBL1306767

Nc1cc(Cl)c(F)cc1I

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ CD44 P16070 1/20 0.36
▸ KDM1A O60341 2/20 0.35
▸ KDM1B Q8NB78 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ SLC6A4 P31645 2/20 0.34
▸ CA1 P00915 4/20 0.31
▸ CA2 P00918 4/20 0.31
▸ CA9 Q16790 4/20 0.31
▸ CA3 P07451 2/20 0.31
▸ TSHR P16473 2/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ CA12 O43570 1/20 0.30
▸ CA4 P22748 1/20 0.30
▸ CA6 P23280 1/20 0.30
▸ CA5A P35218 1/20 0.30
▸ CA7 P43166 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9908757 0.91 ALDH1A1 (0.39) GAAALDH1A1TDP1CD44KDM1A
SCHEMBL31401806 0.81 GAA (0.43) GAAALDH1A1TDP1CD44CA1
SCHEMBL1093491 0.79 ALDH1A1 (0.36) ALDH1A1CA1CA2CA9CA3
SCHEMBL2766461 0.79 GAA (0.53) GAAALDH1A1TDP1CD44CA1
SCHEMBL30788050 0.79 ALDH1A1 (0.36) ALDH1A1CA1CA2CA9CA3
SCHEMBL404239 0.79 GAA (0.53) GAAALDH1A1TDP1CD44KDM1A
SCHEMBL12478277 0.77 GAA (0.67) GAAALDH1A1TDP1CD44KDM1A
SCHEMBL8492289 0.77 GAA (0.50) GAAALDH1A1TDP1CD44KDM1A
SCHEMBL30525059 0.77 ALDH1A1 (0.43) ALDH1A1TDP1KDM1AKDM1BMAPT
SCHEMBL16555486 0.77 GAA (0.50) GAAALDH1A1TDP1CD44CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115697993-B Pyrimidine compounds as AXL inhibitors 南京正大天晴制药有限公司 2024-12-10 — — CN disclosed
US-20230227484-A1 PYRIMIDINE COMPOUND AS AXL INHIBITOR NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) 2023-07-20 — — US disclosed
EP-4163278-A1 PYRIMIDINE COMPOUND AS AXL INHIBITOR Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) 2023-04-12 — — EP disclosed
CN-115697993-A Pyrimidines as AXL inhibitors 南京正大天晴制药有限公司 2023-02-03 — — CN disclosed
WO-2021239133-A1 PYRIMIDINE COMPOUND AS AXL INHIBITOR 南京正大天晴制药有限公司 2021-12-02 — — WO disclosed
EP-2760841-B1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2016-08-24 — — EP disclosed
US-9169246-B2 Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2015-10-27 — — US disclosed
US-9133168-B2 Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors SANOFI (FR) 2015-09-15 — — US disclosed
EP-2573073-B1 Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof SANOFI SA (FR) 2014-10-22 — — EP disclosed
US-20140235616-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-21 — — US disclosed
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases NOVARTIS AG (CH) 2010-05-20 — — US disclosed
EP-1919869-B1 INDOLE DERIVATIVES AS PPAR ACTIVATORS FOURNIER LAB SA (FR) 2010-04-14 — — EP disclosed
CN-101679382-A 3-imidazolyl-indoles for the treatment of proliferative diseases NOVARTIS AG 2010-03-24 — — CN disclosed
EP-2142535-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis Ag (CH) 2010-01-13 — — EP disclosed
EP-2011783-A1 Process for the preparation of an indole derivative F. HOFFMANN-LA ROCHE AG (CH) 2009-01-07 — — EP disclosed
WO-2008119741-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2008-10-09 — — WO disclosed
CN-101248044-A Novel indole compounds FOURNIER LAB SA (FR) 2008-08-20 — — CN disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 — — US disclosed
EP-1919869-A1 NOVEL INDOLE COMPOUNDS LABORATOIRES FOURNIER S.A. (FR) 2008-05-14 — — EP disclosed
WO-2007026097-A1 NOVEL INDOLE COMPOUNDS LABORATOIRES FOURNIER S.A. (FR) 2007-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases MDM4, TP53, MDM2 GAA 3947/4885ALDH1A1 2589/4885TDP1 508/4885
US-20140235616-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CYP11B2, CYP1A2, COQ8A GAA 1631/4885ALDH1A1 97/4885TDP1 750/4885
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP GAA 772/4885ALDH1A1 1607/4885TDP1 424/4885
US-20230227484-A1 PYRIMIDINE COMPOUND AS AXL INHIBITOR AXL, FLT3, TYMP GAA 933/4885ALDH1A1 2696/4885TDP1 1514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback